Selected highlights from the 5th International Conference on Ovarian Cancer

Bibliography

• JEMAL A, MURRAY, WARD E et al.: Cancer statistics, 2005. CA Cancer J. Clin. (2005) 55:10–30.
   PubMedGoogle Scholar
• YOUNG RC, DECKER DG, WHARTON JT et al.: Staging laparotomy in early ovarian cancer. J. Am. Med. Ass. (1983) 250(22):3072–3076.
   PubMed Web of Science ®Google Scholar
• EISENKOP SM, FRIEDMAN RI,, WANG HJ: Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. GynecoL Oncol (1998) 69(2):103–108.
   PubMed Web of Science ®Google Scholar
• ALLEN DG, HEINTZ AP, TOUW FW: A meta-analysis of residual disease and survival in stage III adn IV carcinoma of the ovary. Eur. J. Gynaecol One. (1995) 16(5):349–356.
   PubMedGoogle Scholar
• BRISTOW RE, TOMACRUZ RS, ARMSTRONG DK et al.: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol (2002) 20(5):1248–1259.
   PubMed Web of Science ®Google Scholar
• MCGUIRE WP, HOSKINS WJ, BRADY MF et al.: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Eng. J. Med. (1996) 334(1):1–6.
   PubMed Web of Science ®Google Scholar
• OZOLS RF, BUNDY BN, GREER BE et al.: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a GynecologicOncology Group study. J. Clin. Oncol (2003) 21(17):3194–3200.
   PubMed Web of Science ®Google Scholar
• ALBERTS DS, LIU, PY, HANNIGAN EV et al.: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J. Med. (1996) 335(20:1950–1955.
   PubMedGoogle Scholar
• MARKMAN M, BUNDY BN, ALBERTS DS et al.: Phase III trial of standard-dose intravenous cisplatin plus paclitaxel wrsus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J. Clin. Oncol (2001) 19(4): 1001–1007.
   PubMed Web of Science ®Google Scholar
• ARMSTRONG D, BUNDY B, BAERGEN R et al.: Randomized Phase III study of intravenous (IV) paclitaxel and cisplatin versus IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (0C); a Gynecologic Oncology Group trial (GOG 172). Proc. Am. Soc. Clin. Oncol (2002) 21:201a.
   Web of Science ®Google Scholar
• VON HOFF DD: Human tumor cloning assays: applications in clinical oncology and new antineoplastic agent development. Cancer Met. Rev. (1988) 7(4):357–371.
   PubMedGoogle Scholar
• ORR JW, ORR P, KERN DH: Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance. Cancer J. St-Z. Am. (1999) 5(3):174–178.
   PubMed Web of Science ®Google Scholar
• ELTABBAKH GH, PIVER MS, HEMPLING RE et al.: Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer. GynecoL Oncol (1998) 70(3):392–397.
   PubMedGoogle Scholar
• JAIN RK: Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. (2001) 7(9):987–989.
   PubMed Web of Science ®Google Scholar
• SAFAEI R, KATANO K, SAMIMI G et al.: Cross-resistance to cisplatin in cells with acquired resistance to copper. Cancer Chemother. PharmacoL (2004) 53(3):239–246.
   PubMedGoogle Scholar
• TOWNSEND DM, SHEN H, STAROS AL et al.: Efficacy of a glutathione S-transferase pi-activated prodrug in platinum-resistant ovarian cancer cells. MoL Cancer Ther. (2002) 1(12):1089–1095.
   PubMed Web of Science ®Google Scholar
• -WILLIAMS S, BLESSING JA, LIAO SY et al.: Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group. J. Clin. Oncol (1994) 12(4):701–706.
   PubMedGoogle Scholar
• KURMAN RJ, NORRIS HJ: Malignant germ cell tumors of the ovary. Hum. PathoL (1977) 8(5):551–564.
   PubMedGoogle Scholar
• KURMAN RJ, NORRIS HJ: Endodermal sinus tumor of the ovary: a clinical and pathologic analysis of 71 cases. Cancer (1976) 38(6):2404–2419.
   PubMedGoogle Scholar
• GERSHENSON DM: Management of early ovarian cancer: germ cell and sex cord-stromal tumors. Gynecol. Oncol (1994) 55(3 Pt 2):S62–S72.
   Google Scholar
• BROWN J, SHVARTSMAN HS, DEAVERS MT et al.: The activity of taxanes in the treatment of sex cord-stromal ovarian tumors. J. Clin. Oncol (2004) 22(17):3517–3523.
   PubMed Web of Science ®Google Scholar
• MILLIKEN D, SCOTTON C, RAJU S et al.: Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites. Clin. Cancer Res. (2002) 8(4):1108–1114.
   PubMedGoogle Scholar
• SCOTTON CJ, WILSON JL, MILLIKEN D et al.: Epithelial cancer cell migration: a role for chemokine receptors? Cancer Res. (2001) 61(13):4961–4965.
   Google Scholar
• LIANG Z, WU T, LOU H et al.: Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res. (2004) 64(12):4302–4308.
   PubMed Web of Science ®Google Scholar
• BASELGA J, HAMMOND LA: HER-targeted tyrosine-kinase inhibitors. Oncology (2002) 1:6–16.
   Google Scholar
• SCHILDER RJ, KOHN E, SILL MW et al.: Phase II trial of gefitinib in patients with recurrent ovarian or primary peritoneal cancer: Gynecologic Oncology Group 170 c. Proc. Am. Soc. Clin. Oncol (2003) 22(1814a):451.
   Google Scholar
• LYNCH TJ, BELL DW, SORDELLA R et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Eng. J. Med. (2004) 350(21):2129–2139.
   PubMed Web of Science ®Google Scholar
• SIEGEL BA, DEHDASHTI F, MUTCH DG et al.: Evaluation of 111In-DTPA-Folate as a Receptor-Targeted Diagnostic Agent for Ovarian Cancer: Initial Clinical Results. J. Nud Med. (2003) 44(5):700–707.
   Google Scholar
• BARNES MN, BERRY WD, STRAUGHN JM et al.: A pilot study of ovarian cancer chemoprevention using medroxyprogesterone acetate in an avian model of spontaneous ovarian carcinogenesis. Gynecol Oncol (2002) 87(1):57–63.
   PubMedGoogle Scholar
• NAROD SA, RISCH H, MOSLEHI R et al.: Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Eng-. J. Med. (1998) 339(7):424–428.
   Google Scholar
• EISENKOP SM, FRIEDMAN RL, SPIRTOS NM: The role of secondary cytoreductive surgery in the treatment of patients wtih recurrent epithelial ovarian carcinoma. Cancer (2000) 88(1):144–153.
   PubMed Web of Science ®Google Scholar
• TAY E-H, GRANT PT, GEBSKI Vet al: Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstet. Gynecol (2002) 99(0:1008–1013.
   PubMedGoogle Scholar
• ZANG RY, ZHANG ZY, LI ZT et ed.: Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer. J. Surg-. Oncol (2000) 75(1):24–30.
   Google Scholar